Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 61 Carcinoma, Renal Cell 39 Neoplasm Metastasis 38 Neoplasms 24 Kidney Neoplasms 20 Neuroendocrine Tumors 19 Recurrence 16 Prostatic Neoplasms 15 Head and Neck Neoplasms 13 Tuberous Sclerosis 12 Triple Negative Breast Neoplasms 12 Lymphoma, Mantle-Cell 11 Hodgkin Disease 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma 10 Colorectal Neoplasms 10 Waldenstrom Macroglobulinemia 9 Stomach Neoplasms 9 Multiple Myeloma 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Glioma 9 Glioblastoma 9 Brain Neoplasms 9 Sarcoma 8 Pancreatic Neoplasms 8 Melanoma 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8

Interventions

talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 mirdametinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neurofibroma × Everolimus × Clear all

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡